Inhibrx Valor da empresa
Qual é o Valor da empresa de Inhibrx?
O Valor da empresa de Inhibrx, Inc. é $1.31B
Qual é a definição de Valor da empresa?
O valor da empresa é uma medida do valor total de mercado de uma empresa. É calculado como capitalização de mercado com dívida, participação minoritária e ações preferenciais menos o total de caixa e equivalentes de caixa.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Valor da empresa de empresas na Setor Health Care em NASDAQ em comparação com Inhibrx
O que Inhibrx faz?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Empresas com valor da empresa semelhantes a Inhibrx
- Godrej Agrovet tem Valor da empresa de $1.31B
- Savencia SA tem Valor da empresa de $1.31B
- Green Plains Inc tem Valor da empresa de $1.31B
- Network18 Media & Investments tem Valor da empresa de $1.31B
- Welspun India tem Valor da empresa de $1.31B
- GIC Housing Finance tem Valor da empresa de $1.31B
- Inhibrx tem Valor da empresa de $1.31B
- Magyar Telekom Telecommunications Plc tem Valor da empresa de $1.31B
- Desktop Metal tem Valor da empresa de $1.31B
- PTC India tem Valor da empresa de $1.32B
- Score Media and Gaming tem Valor da empresa de $1.32B
- Ironwood Pharmaceuticals Inc tem Valor da empresa de $1.32B
- Social Capital Hedosophia Holdi tem Valor da empresa de $1.32B